世界の多嚢胞性卵巣症候群（PCOS）治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4731 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、多嚢胞性卵巣症候群（PCOS）治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口避妊薬、排卵誘発剤、顔面発毛阻害剤、インスリン感作剤）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・多嚢胞性卵巣症候群（PCOS）治療薬の市場動向 ・企業の競争状況、市場シェア ・多嚢胞性卵巣症候群（PCOS）治療薬の種類別市場規模と予測2016-2027（経口避妊薬、排卵誘発剤、顔面発毛阻害剤、インスリン感作剤） ・多嚢胞性卵巣症候群（PCOS）治療薬の用途別市場規模と予測2016-2027（病院、クリニック、その他） ・多嚢胞性卵巣症候群（PCOS）治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・多嚢胞性卵巣症候群（PCOS）治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・多嚢胞性卵巣症候群（PCOS）治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・多嚢胞性卵巣症候群（PCOS）治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・多嚢胞性卵巣症候群（PCOS）治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bristol Myers Squibb、Crinetics Pharmaceuticals, Inc.、EffRx, Inc.、Ferring Pharmaceuticals、Merck KGaA、Neurocrine Biosciences, Inc.、Novartis Pharmaceuticals、Pfizer Inc.、Sanofi Aventis、Teva Pharmaceutical Industries Limited） ・結論

Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. 

Market Analysis and Insights: Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market
The global Polycystic Ovarian Syndrome (PCOS) Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Polycystic Ovarian Syndrome (PCOS) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Polycystic Ovarian Syndrome (PCOS) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Polycystic Ovarian Syndrome (PCOS) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Polycystic Ovarian Syndrome (PCOS) Therapeutics market.

Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Scope and Market Size
Polycystic Ovarian Syndrome (PCOS) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Polycystic Ovarian Syndrome (PCOS) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Oral Contraceptive
Ovulation Inducing Agents
Facial Hair Growth Inhibitor
Insulin Sensitizing Agent

Segment by Application
Hospitals
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bristol Myers Squibb
Crinetics Pharmaceuticals, Inc.
EffRx, Inc.
Ferring Pharmaceuticals
Merck KGaA
Neurocrine Biosciences, Inc.
Novartis Pharmaceuticals
Pfizer Inc.
Sanofi Aventis
Teva Pharmaceutical Industries Limited

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral Contraceptive
1.2.3 Ovulation Inducing Agents
1.2.4 Facial Hair Growth Inhibitor
1.2.5 Insulin Sensitizing Agent
1.3 Market by Application
1.3.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Perspective (2016-2027)
2.2 Polycystic Ovarian Syndrome (PCOS) Therapeutics Growth Trends by Regions
2.2.1 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Polycystic Ovarian Syndrome (PCOS) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Polycystic Ovarian Syndrome (PCOS) Therapeutics Industry Dynamic
2.3.1 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Trends
2.3.2 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Drivers
2.3.3 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Challenges
2.3.4 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Players by Revenue
3.1.1 Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue
3.4 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Concentration Ratio
3.4.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue in 2020
3.5 Polycystic Ovarian Syndrome (PCOS) Therapeutics Key Players Head office and Area Served
3.6 Key Players Polycystic Ovarian Syndrome (PCOS) Therapeutics Product Solution and Service
3.7 Date of Enter into Polycystic Ovarian Syndrome (PCOS) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Polycystic Ovarian Syndrome (PCOS) Therapeutics Breakdown Data by Type
4.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Polycystic Ovarian Syndrome (PCOS) Therapeutics Breakdown Data by Application
5.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2016-2027)
6.2 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type
6.2.1 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2027)
6.3 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application
6.3.1 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2027)
6.4 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country
6.4.1 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2016-2027)
7.2 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type
7.2.1 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application
7.3.1 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country
7.4.1 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2016-2027)
9.2 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type
9.2.1 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application
9.3.1 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country
9.4.1 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Company Details
11.1.2 Bristol Myers Squibb Business Overview
11.1.3 Bristol Myers Squibb Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.1.4 Bristol Myers Squibb Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
11.1.5 Bristol Myers Squibb Recent Development
11.2 Crinetics Pharmaceuticals, Inc.
11.2.1 Crinetics Pharmaceuticals, Inc. Company Details
11.2.2 Crinetics Pharmaceuticals, Inc. Business Overview
11.2.3 Crinetics Pharmaceuticals, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.2.4 Crinetics Pharmaceuticals, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
11.2.5 Crinetics Pharmaceuticals, Inc. Recent Development
11.3 EffRx, Inc.
11.3.1 EffRx, Inc. Company Details
11.3.2 EffRx, Inc. Business Overview
11.3.3 EffRx, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.3.4 EffRx, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
11.3.5 EffRx, Inc. Recent Development
11.4 Ferring Pharmaceuticals
11.4.1 Ferring Pharmaceuticals Company Details
11.4.2 Ferring Pharmaceuticals Business Overview
11.4.3 Ferring Pharmaceuticals Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.4.4 Ferring Pharmaceuticals Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
11.4.5 Ferring Pharmaceuticals Recent Development
11.5 Merck KGaA
11.5.1 Merck KGaA Company Details
11.5.2 Merck KGaA Business Overview
11.5.3 Merck KGaA Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.5.4 Merck KGaA Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
11.5.5 Merck KGaA Recent Development
11.6 Neurocrine Biosciences, Inc.
11.6.1 Neurocrine Biosciences, Inc. Company Details
11.6.2 Neurocrine Biosciences, Inc. Business Overview
11.6.3 Neurocrine Biosciences, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.6.4 Neurocrine Biosciences, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
11.6.5 Neurocrine Biosciences, Inc. Recent Development
11.7 Novartis Pharmaceuticals
11.7.1 Novartis Pharmaceuticals Company Details
11.7.2 Novartis Pharmaceuticals Business Overview
11.7.3 Novartis Pharmaceuticals Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.7.4 Novartis Pharmaceuticals Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
11.7.5 Novartis Pharmaceuticals Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Details
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.8.4 Pfizer Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
11.8.5 Pfizer Inc. Recent Development
11.9 Sanofi Aventis
11.9.1 Sanofi Aventis Company Details
11.9.2 Sanofi Aventis Business Overview
11.9.3 Sanofi Aventis Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.9.4 Sanofi Aventis Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
11.9.5 Sanofi Aventis Recent Development
11.10 Teva Pharmaceutical Industries Limited
11.10.1 Teva Pharmaceutical Industries Limited Company Details
11.10.2 Teva Pharmaceutical Industries Limited Business Overview
11.10.3 Teva Pharmaceutical Industries Limited Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Limited Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
11.10.5 Teva Pharmaceutical Industries Limited Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Oral Contraceptive
Table 3. Key Players of Ovulation Inducing Agents
Table 4. Key Players of Facial Hair Growth Inhibitor
Table 5. Key Players of Insulin Sensitizing Agent
Table 6. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Regions (2016-2021)
Table 10. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Regions (2022-2027)
Table 12. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Trends
Table 13. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Drivers
Table 14. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Challenges
Table 15. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Restraints
Table 16. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Players (2016-2021)
Table 18. Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics as of 2020)
Table 19. Ranking of Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Polycystic Ovarian Syndrome (PCOS) Therapeutics Product Solution and Service
Table 23. Date of Enter into Polycystic Ovarian Syndrome (PCOS) Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Type (2016-2021)
Table 27. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Application (2016-2021)
Table 31. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 63. Bristol Myers Squibb Company Details
Table 64. Bristol Myers Squibb Business Overview
Table 65. Bristol Myers Squibb Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 66. Bristol Myers Squibb Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021) & (US$ Million)
Table 67. Bristol Myers Squibb Recent Development
Table 68. Crinetics Pharmaceuticals, Inc. Company Details
Table 69. Crinetics Pharmaceuticals, Inc. Business Overview
Table 70. Crinetics Pharmaceuticals, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 71. Crinetics Pharmaceuticals, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021) & (US$ Million)
Table 72. Crinetics Pharmaceuticals, Inc. Recent Development
Table 73. EffRx, Inc. Company Details
Table 74. EffRx, Inc. Business Overview
Table 75. EffRx, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 76. EffRx, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021) & (US$ Million)
Table 77. EffRx, Inc. Recent Development
Table 78. Ferring Pharmaceuticals Company Details
Table 79. Ferring Pharmaceuticals Business Overview
Table 80. Ferring Pharmaceuticals Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 81. Ferring Pharmaceuticals Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021) & (US$ Million)
Table 82. Ferring Pharmaceuticals Recent Development
Table 83. Merck KGaA Company Details
Table 84. Merck KGaA Business Overview
Table 85. Merck KGaA Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 86. Merck KGaA Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021) & (US$ Million)
Table 87. Merck KGaA Recent Development
Table 88. Neurocrine Biosciences, Inc. Company Details
Table 89. Neurocrine Biosciences, Inc. Business Overview
Table 90. Neurocrine Biosciences, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 91. Neurocrine Biosciences, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021) & (US$ Million)
Table 92. Neurocrine Biosciences, Inc. Recent Development
Table 93. Novartis Pharmaceuticals Company Details
Table 94. Novartis Pharmaceuticals Business Overview
Table 95. Novartis Pharmaceuticals Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 96. Novartis Pharmaceuticals Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021) & (US$ Million)
Table 97. Novartis Pharmaceuticals Recent Development
Table 98. Pfizer Inc. Company Details
Table 99. Pfizer Inc. Business Overview
Table 100. Pfizer Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021) & (US$ Million)
Table 101. Pfizer Inc. Recent Development
Table 102. Sanofi Aventis Company Details
Table 103. Sanofi Aventis Business Overview
Table 104. Sanofi Aventis Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 105. Sanofi Aventis Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021) & (US$ Million)
Table 106. Sanofi Aventis Recent Development
Table 107. Teva Pharmaceutical Industries Limited Company Details
Table 108. Teva Pharmaceutical Industries Limited Business Overview
Table 109. Teva Pharmaceutical Industries Limited Polycystic Ovarian Syndrome (PCOS) Therapeutics Product
Table 110. Teva Pharmaceutical Industries Limited Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021) & (US$ Million)
Table 111. Teva Pharmaceutical Industries Limited Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Oral Contraceptive Features
Figure 3. Ovulation Inducing Agents Features
Figure 4. Facial Hair Growth Inhibitor Features
Figure 5. Insulin Sensitizing Agent Features
Figure 6. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Clinic Case Studies
Figure 9. Others Case Studies
Figure 10. Polycystic Ovarian Syndrome (PCOS) Therapeutics Report Years Considered
Figure 11. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Regions: 2020 VS 2027
Figure 14. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Regions (2022-2027)
Figure 15. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Players in 2020
Figure 16. Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue in 2020
Figure 18. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Type (2016-2021)
Figure 19. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Type (2022-2027)
Figure 20. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Type (2016-2027)
Figure 22. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Application (2016-2027)
Figure 23. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Country (2016-2027)
Figure 24. United States Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Type (2016-2027)
Figure 28. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Application (2016-2027)
Figure 29. Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Country (2016-2027)
Figure 30. Germany Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Region (2016-2027)
Figure 40. China Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Type (2016-2027)
Figure 48. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Application (2016-2027)
Figure 49. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Country (2016-2027)
Figure 50. Mexico Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Country (2016-2027)
Figure 56. Turkey Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Bristol Myers Squibb Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
Figure 60. Crinetics Pharmaceuticals, Inc. Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
Figure 61. EffRx, Inc. Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
Figure 62. Ferring Pharmaceuticals Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
Figure 63. Merck KGaA Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
Figure 64. Neurocrine Biosciences, Inc. Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
Figure 65. Novartis Pharmaceuticals Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
Figure 66. Pfizer Inc. Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
Figure 67. Sanofi Aventis Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
Figure 68. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---